

### Long Term Care Formulary

RS - 44

Eong Form Oaro Formalary		
SECTION	SUBJECT	PAGE
RESTRICTED USE	Basal insulins (insulin glargine and detemir)	1 of 1
	Original	<b>YY MM DD</b> 14 09 26

Coverage for basal insulin products shall be granted provided the following conditions are met:

## PROTOCOL 1

- With insulin-dependent diabetes clients that have experienced uncontrolled hypoglycemia, particularly nocturnal or unpredictable, **AND**
- When dose reductions of NPH insulin have not successfully managed uncontrolled hypoglycemia. Relaxed glycemic targets (or HgB A1c) can be achieved with NPH used in conservative doses to minimize hypoglycemic risk, AND
- When a trial of insulin glargine or detemir for a period of fourteen (14) days have been demonstrated to be effective for managing uncontrolled hypoglycemia. Glycemic control values prior to the trial and during the trial must be indicated on the HCD funding request form.

# <u>Or</u>

## PROTOCOL 2

• When consultation with an Endocrinologist or Internist, results in recommendations for use when patients have not met glycemic control with other conventional basal insulins.

#### NOTES:

- Do not mix or dilute with other insulins or solutions.
- Vials should be stored in the refrigerator and not allowed to freeze.
- Vials in use may be kept un-refrigerated for up to 30-42 days (as directed by manufacturer check product monograph), protected from direct heat & light.

© 2014 Alberta Health Services. This material is provided on an "as is", "where is" basis. Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.